Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (PKI) drives innovation in diagnostics, life sciences, and applied markets through advanced scientific solutions. This page aggregates official announcements and verified news about the company's strategic initiatives, financial performance, and technological advancements.
Investors and industry professionals will find timely updates on earnings reports, product launches, and regulatory milestones. Our curated collection simplifies tracking PKI's progress in enabling critical research and improving healthcare outcomes globally.
Key content includes updates on analytical instrumentation developments, partnership announcements with research institutions, and expansions in diagnostic testing capabilities. All materials adhere to strict factual reporting standards without speculative commentary.
Bookmark this page for streamlined access to PerkinElmer's latest corporate communications. Check back regularly for insights into how PKI continues to address complex challenges in scientific discovery and clinical diagnostics.
PerkinElmer, a leader in the life sciences sector, has unveiled the EnVision® Nexus™ system, its most advanced multimode plate reader, at SLAS2023. This innovative platform enhances high-throughput screening (HTS) capabilities, significantly supporting drug discovery by allowing researchers to screen millions of samples with improved speed and accuracy. Additionally, PerkinElmer introduced the Zephyr® G3 NGS iQ™ workstation for automating NGS library preparation, further enhancing laboratory efficiency. With its robust portfolio and commitment to advancing scientific research, PerkinElmer aims to drive R&D productivity across various applications.
PerkinElmer (NYSE: PKI) will present at the Cowen 43rd Annual Health Care Conference on March 6 at 9:10 a.m. ET, with CFO Max Krakowiak, and the Barclays Global Healthcare Conference on March 14 at 8:00 a.m. ET, featuring CEO Prahlad Singh. The presentations will provide updates on the company's strategic priorities. Audio webcasts will be available on their website and replays will be accessible for 30 days.
PerkinElmer reported Q4 2022 revenue of $741 million, down from $1,028 million year-over-year, resulting in a 28% decline. The GAAP EPS was $0.85, down from $1.45 a year ago. Full-year revenue also decreased, totaling $3,312 million, compared to $3,828 million in 2021. Operating income dropped significantly, with a GAAP operating profit margin of 22.4% compared to 32.9% the previous year. Despite a challenging year, the company anticipates a 2023 revenue forecast of $2.94 billion with adjusted EPS of $5.05.
The Board of Directors of PerkinElmer (NYSE: PKI) has declared a regular quarterly dividend of
Amphenol Corporation (NYSE: APH) has appointed Dr. Prahlad Singh to its board of directors, expanding the board to 10 members. Dr. Singh, who is currently the President and CEO of PerkinElmer (NYSE: PKI), boasts over 25 years of global leadership experience in the healthcare and technology sectors. His background includes senior roles in major companies such as GE Healthcare and Philips Healthcare. The board views his extensive expertise in technology and mergers as valuable for Amphenol's growth strategy.
PerkinElmer Inc. (NYSE: PKI) will release its fourth quarter and full year 2022 financial results on February 14, 2023, before market open. A conference call led by CEO Prahlad Singh and CFO Max Krakowiak will take place at 8:00 a.m. ET on the same day. The company has updated its guidance for Q4 2022, anticipating results that will meet or exceed earlier projections made on November 8, 2022. PerkinElmer is a leader in life sciences and diagnostics, reporting about $5 billion in revenue in 2021 and operating in 190 countries.
PerkinElmer, a leader in health innovation, will present at the J.P. Morgan Healthcare Conference on January 10, 2023, at 8:15 a.m. PT. CEO Prahlad Singh is set to discuss the company's strategic priorities. Interested parties can access a live audio webcast of the presentation via a designated page, with a replay available on PerkinElmer's Investor Relations website for 30 days post-event. The company reported revenues of approximately $5 billion in 2021 and serves customers in 190 countries.
PerkinElmer has announced FDA authorization for its EONIS™ SCID-SMA assay kit, the first-ever FDA-approved screening for spinal muscular atrophy (SMA) in newborns in the US. This in vitro diagnostic test enables simultaneous detection of SMA and severe combined immunodeficiency (SCID) using a single dried blood spot. Early detection is crucial, as both conditions can lead to severe health issues. The EONIS Platform integrates advanced PCR technology and enhances laboratory efficiency. With a proven track record, PerkinElmer aims to help save the lives of approximately 70 babies daily.
PerkinElmer (NYSE: PKI), a leading global innovator for a healthier world, will present at the 2022 Stifel Healthcare Conference on November 16, 2022, at 9:10 a.m. ET in New York, NY. Max Krakowiak, the CFO, will discuss the company's strategic priorities during a fireside chat. Interested attendees can register here. A live audio webcast will be available on the investor relations website, with a replay accessible for 90 days.
PerkinElmer reported third quarter 2022 results, revealing a GAAP EPS from continuing operations of $0.55, down from $0.94 a year ago. Revenue decreased 17% year-over-year to $712 million, with pro forma revenue at $1.03 billion, reflecting a 12% organic growth excluding COVID-related impacts. The company anticipates fourth quarter revenue of approximately $0.73 billion and full year revenue of $3.30 billion. Adjusted EPS for the quarter was $1.51, compared to $2.31 last year. Challenges persist in the Diagnostics segment, which saw a 39% decline in revenue.
FAQ
What is the market cap of PERKINELMER (PKI)?
